Month: March 2023

In connection with Borregaard’s Annual General Meeting, Mr. Per A. Sørlie, President and CEO of Borregaard ASA, has been assigned voting rights based on proxies for 7,297,565 shares in Borregaard ASA. The proxies apply exclusively to the Annual General Meeting in Borregaard ASA on 18 April 2023. This means that Mr. Per A. Sørlie represents a total of 7,30 % of the outstanding shares in Borregaard ASA. Mr. Per A. Sørlie’s personal shareholding in Borregaard ASA is 164,810 shares. Borregaard ASASarpsborg, 29 March 2023 Contact:Lotte Kvinlaug, Investor Relations Officer, +47 922 86 909 This information is subject to the disclosure requirements pursuant to Section 5 -12 of the Norwegian Securities Trading Act.  

PRESS RELEASE – REGULATED INFORMATION 29 March 2023, 07:00 CEST Biocartis To Publish 2022 Annual Report on 11 April 2023 Mechelen, Belgium, 29 March 2023 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that it will publish its 2022 annual report on 11 April 2023, which is later than the previously communicated publication date, because the audit of the consolidated financial statements is not finalized with respect to the accounting treatment and the presentation of the various recapitalization transactions that completed on 16 January 2023. Biocartis’ 2022 annual report will be published simultaneously with the invitation to its annual shareholders’ meeting that will be held on Friday 12 May 2023 at 2:00 p.m. CEST at the offices of...

The Management Board of EfTEN Real Estate Fund AS (previous business name EfTEN Real Estate Fund III AS; registry code 12864036; seat Tallinn, A. Lauteri 5) calls an annual general meeting of shareholders on 20 April 2023 at 10:00. Venue of the general meeting: Swissôtel Tallinn Conference Center at Tallinn, Tornimäe 3. The registration of participants of the general meeting starts at 09:00 on 20 April 2023 at the venue of the meeting. The registration ends at 10:00. If possible, we request that all shareholders arrive in time considering the time required to register the participants of the meeting. The list of shareholders who shall be entitled to participate in the annual general meeting shall be fixed seven days prior to the date of the general meeting, i.e., on 13 April 2023 as at the end of the working day of the registrar of the...

MCH Group: Significantly improved figures on previous year The key figures for MCH Group’s 2022 annual results are significantly up on the previous year. MCH Group was able to increase both its sales and its EBITDA by over 60 % compared with the previous year; the net loss was reduced to CHF 9.3 million. Consolidated key figures at a glance (figures for 2021 in brackets)Operating income: CHF 394.1 million (CHF 243.3 million) EBITDA: CHF 14.0 million (CHF 8.5 million) Loss for the year: CHF -9.3 million (CHF -17.3 million) Equity: CHF 113.3 million / 25.5% (CHF 47.8 million / 11.8%) Cash and cash equivalents: CHF 151.9 million (CHF 113.7 million) Net debt: CHF 84.6 million (CHF 132.7 million)The first trimester of 2022 was still strongly marked by the continuing effects of the Covid 19 pandemic. MCH Group estimates that the negative...

On 28 March 2023 UAB Merko Statyba, part of AS Merko Ehitus group, and UAB Vėjas LT, part of E energija group, entered into the contract to perform the construction of foundations for 16 wind turbines, electrical cables and roads in a windfarm located in the Kelmė district, Lithuania. The contract value is approximately EUR 30 million, plus value added tax. The project is scheduled to be completed in the second quarter of 2025. UAB Merko Statyba (merko.lt) is Lithuanian construction company, which offers construction services in the fields of general construction and residential construction. Additional information: UAB Merko Statyba, Construction Director Mr. Jaanus Rästas, phone: +370 6875 0680. Urmas SomelarHead of FinanceAS Merko Ehitus+372 650 1250urmas.somelar@merko.ee AS Merko Ehitus (group.merko.ee) group companies develop real...

Oslo, 29 March 2023 – DNO ASA, the Norwegian oil and gas operator, today announced that it has started an orderly shutdown of its operated oil fields in the Kurdistan region of Iraq four days after it was instructed to temporarily cease deliveries to the Iraq-Turkey Pipeline destined for the Mediterranean port of Ceyhan following an arbitration ruling in favor of Iraq against Turkey for exporting Kurdish oil without Baghdad’s approval. DNO had diverted oil production to storage tanks, but capacity is limited, as previously announced. The Company’s prolific Tawke and Peshkabir fields averaged combined production of 107,000 barrels of oil per day in 2022, representing a quarter of Kurdistan’s total exports. Peshkabir production was halted last night and plans drawn up to conduct deferred maintenance. Tawke production shutdown has started...

Today, Beter Bed Holding N.V. (BBH) – the Netherlands’ largest sleep specialist in retail, wholesale and B2B – has published the notice and agenda for its Annual General Meeting (AGM) to be held on Wednesday, 10 May 2023. During the AGM, BBH will look back on the results achieved over 2022, and update the shareholders on the current developments. The agenda for the AGM and the notice are available on the Company’s website www.beterbedholding.com. About Beter Bed HoldingBeter Bed Holding (BBH) is the Netherlands’ leading sleep specialist in retail, wholesale and B2B. Our mission is simple. We believe that the better we sleep, the happier, healthier and more productive we are. And we won’t rest until everyone gets the high-quality sleep they deserve. Listed on Euronext Amsterdam, BBH operates the successful retail brands Beter Bed, Beddenreus,...

Ad hoc announcement pursuant to Art. 53 LR CFO Martin Klöti to leave Schweiter TechnologiesMartin Klöti, Chief Financial Officer (CFO) and member of the Management of Schweiter Technologies, has decided to leave the companySteinhausen, 29 March 2023 – Martin Klöti, who has been with Schweiter Technologies since 2003 and CFO of the Group since 2014, has decided to leave the Management as of September 2023 to take up a new position outside the company. The Board of Directors will be sorry to see him leave and wishes to take this opportunity to thank him for his many years of dedicated service and his enormous contribution to the development of Schweiter Technologies. The search for his successor will be initiated forthwith. For further information please contact: Martin Klöti, CFO Tel. +41 41 757 77 00 investor@schweiter.com ABOUT SCHWEITER Schweiter...

MISSISSAUGA, Ontario, March 28, 2023 (GLOBE NEWSWIRE) — goeasy Ltd. (TSX: GSY), (“goeasy” or the “Company”), one of Canada’s leading non-prime consumer lenders, has provided an update regarding the Government of Canada’s intent to change the maximum allowable rate of interest outlined within the Federal Budget presented on March 28, 2023, and an update on recent enhancements that increase its sources of funding capacity. Update on the Federal Budget On March 28, 2023, the Federal Government announced its plan to reduce the maximum allowable rate of interest to an annual percentage rate of 35% (APR), prior to releasing the results of the recent Department of Finance consultation. Consequences for Canadian Consumers – goeasy has been actively engaged in the Federal Government consultation process, both directly and in partnership...

— The two parties will collaborate to develop and commercialize toripalimab in 9 Southeast Asian countries through a joint venture company, Excellmab — Excellmab will be responsible for the development, medical affairs, production of finished products, and commercialization of toripalimab within the cooperation territory. The profits available for distribution by Excellmab will be distributed in proportion to the respective shareholdings of the parties — Using the Excellmab platform, the two parties also plan to collaborate extensively to introduce more high-quality innovative drugs into Southeast Asian markets to achieve joint and long-term development — According to the progress of toripalimab’s R&D and other projects, Junshi Biosciences may receive a milestone payment of up to approximately US$4.52 million,...